Antibody–drug conjugates after EGFR-TKI resistance in EGFR-mutant NSCLC: Evidence boundaries, post-progression reassessment, and therapeutic sequencing

Critical Reviews in Oncology/Hematology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles